Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
The objective of this report is to develop and analyse the commercial proposition of “Respon Therapeutics” in the management of chronic inflammatory skin diseases. “Respon Therapeutics” is a proprietary platform precision drug-delivery system developed by Professor Dang’s Laboratory for the manageme...
Autor principal: | Yamini, Prashanth |
---|---|
Outros Autores: | Dang Thuy Tram |
Formato: | Final Year Project (FYP) |
Idioma: | English |
Publicado em: |
Nanyang Technological University
2024
|
Assuntos: | |
Acesso em linha: | https://hdl.handle.net/10356/177425 |
Registos relacionados
-
In vivo evaluation of sweet potato leaf (Ipomoea batatas (L.)Lam.) extracts for treatment of psoriasis using mouse model
Por: Sani, Anuar
Publicado em: (2017) -
Validation of the recap of atopic eczema (RECAP) measurement instrument for eczema control in adult patients in an Asian clinical setting
Por: Yew, Yik Weng, et al.
Publicado em: (2024) -
How to use the harmonising outcome measures for eczema core outcome set for atopic dermatitis trials: a users' guide
Por: Thomas, Kim S., et al.
Publicado em: (2024) -
Development and validation of the Dermatology Social Comparison (DSC) Scale
Por: Choi, Ellie, et al.
Publicado em: (2024) -
A machine-learning exploration of the exposome from preconception in early childhood atopic eczema, rhinitis and wheeze development
Por: Dong, Yizhi, et al.
Publicado em: (2024)